Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it repurchased 38,800 H-shares on 17 November 2026 via the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HK$3.24 to HK$3.275 each, translating into a volume-weighted average cost of HK$3.258 and an aggregate consideration of HK$0.13 million.
Post-transaction, the company’s issued share capital (excluding treasury shares) decreased marginally by 0.0009 % to 4.45 billion shares, while treasury shares rose to 70.57 million. Total issued shares remained unchanged at 4.52 billion.
The purchase formed part of the repurchase mandate granted on 29 May 2026, which authorises Weigao Group to buy back up to 446.46 million shares. Including the latest transaction, the company has repurchased 13.25 million shares to date, representing 2.97 % of the issued share base when the mandate was approved.
All repurchased shares have been retained as treasury stock, and no shares have been cancelled. Under Hong Kong listing rules, Weigao Group is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 December 2026.
Comments